cyrilzakka/clinical-trials huggingface dataset:
Early Diagnosis of Patients With Mild Cognitive Impairment Through the Parameterization of Functional Tests.

The present study aims to develop an index formed by the variables, functional tests, scales and instruments that best discriminate between healthy subjects and subjects with MCI and that allows the stratification of different levels of severity of MCI, and to validate new systems for the early diagnosis of subjects with mild cognitive impairment.

Dementia affects 46.8 million people and in 2050 it is expected that there will be between 115-135 million people suffering from dementia. Inside dementias, Mild Cognitive Impairment (MCI) has a prevalence in adults aged ≥65 years of 10-20%.

Patients with MCI also show greater progression towards dementia, higher mortality and disability, and a greater use of medical care compared to cognitively normal subjects that converts MCI into an important public health problem, which reinforces the need to perfect clinic assessment procedures to improve the early identification of individuals with MCI. Early diagnosis could allow effective medical treatments that prevent or slow the onset of dementia, and could improve the effectiveness of non-pharmacological interventions.

Currently, it can be used an Inertial Sensor and 3D motion capture systems with a camera to analyse kinematics and these instruments are being integrated as a rehabilitation tool in patients. The use of Inertial Sensor and 3D motion capture cameras would help to find fast and cheap assessment methods for professionals.

Eligibility Criteria:
Inclusion Criteria:

* Subjects over 60 years of age.
* Healthy subjects and subjects diagnosed with mild cognitive impairment.
* Subjects able of filling out questionnaires and performing functional tests.

Exclusion Criteria:

* Participants with neurological pathologies other than mild cognitive impairment.
* Participation in an experimental study where they receive a treatment.
* Score on the Mini-Mental State Examination of less than 24.
* Inability to get up from the chair at least 5 times or 30 seconds
* Inability to walk 20 meters.
* Inability to raise up both arms to 90 degrees or lifting 2 kg with the hand.
* Inability to walk independently without a walking assistance device (cane, crutch or walker).
* Patients with prescription of beta-blockers.
* Inability to provide informed consent.
Impact of Covid-19 on Rhinovirus Epidemic

Rhinovirus (RV) has long been known as the main etiological agent of "common colds" among children and adults. Indeed, RV is involved in more than 50% of upper respiratory tract infections (URTIs), mostly characterized by nasal congestion, rhinorrhea, sore throat and cough. RV can also cause mild to severe lower respiratory tract infections (LRTIs) such as acute bronchiolitis, pneumonia and exacerbations of underlying chronic lung diseases. RV circulates worldwide, especially in temperate climate zones (i.e. many areas of the USA and Europe) and is responsible for annual outbreaks from early fall to the end of spring.

The covid-19 pandemic in 2020 seemed to interfere with the usual seasonal epidemics. For example, the winter Respiratory Syncytial Virus (RSV) epidemic in Lyon, France, was delayed for several months and reduced by half in terms of incidence of hospitalization cases. This can be explained by the widespread deployment of barrier gestures and social distancing measures, known as "non pharmacological interventions" (NPI).

However, the Covid-19 pandemic doesn't seem to have the same reducing impact on Rhinovirus epidemic. A better understanding of viral interactions and factors influencing RV epidemiology as well as the identification of populations at greater risk are required to improve preventive strategies and reduce the burden of Rhinovirus.


Eligibility Criteria:
Inclusion Criteria:

* - Child hospitalized at the " Hopital Femme Mere Enfant ", Lyon, France
* Positive rhinovirus-PCR

Exclusion Criteria:

* - parent's refusal to participate
Epidemiology of Cardiac Development in Youth

To document normal developmental changes in cardiac structure and function during late childhood and adolescence.

DESIGN NARRATIVE:

The investigators documented the nature and extent of changes in cardiac structure based on M-mode measurements and developed corresponding reference values. They documented the nature and extent of changes in cardiac function based on pulse Doppler measures and indices and developed corresponding reference values. They also investigated clinical findings based on M-mode and Doppler measurements as well as changes in body size and composition, sexual maturation, and other covariates. They used existing data from Project HeartBeat! 's 12 four-monthly examinations over the age range from 8 to 17 years.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Eligibility Criteria:
No eligibility criteria
Dietary Perceptions and Practices in Chinese Psoriasis Patients

The influences of diet on psoriasis have been long discussed. As reported in previous publications, a majority of U.S. psoriasis population show high interest in the role of diet on their skin conditions. Given the distinct traditional perceptions and lifestyles in China, the dietary beliefs and behaviors in Chinese psoriasis patients would be very likely to show different patterns. Nevertheless, the information of this large population is still unknown. In this regard, the investigators conduct a questionnaire-based survey, aiming to assess the dietary perceptions and behaviors of Chinese psoriasis patients.

A total of 25 medical institutions all over China participated in the survey. Psoriasis patients surveyed were from both outpatient and inpatient dermatology departments. Researchers from each institution were trained for assisting patients to fill the questionnaire. Each participant filled the online-based questionnaire anonymously in a private setting. The questionnaire consisted of 54 main questions and extended questions, concerning the profile of disease conditions, perceptions and behaviors of diet in their daily life.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years old.
* Confirmed diagnosis of psoriasis.
* Duration of psoriasis ≥ 3 years.
* Must be able to read and understand the questionnaire.
* Receive a full explanation of the purpose and content of the trial before the study begins, and voluntarily sign a written consent form.

Exclusion Criteria:

* Unable to read or understand the questionnaire.
* Other conditions deemed by the investigator to be inappropriate for this study.
Clinical Investigation of Visual Function After Bilateral Implantation of Two Presbyopia-Correcting Trifocal Intraocular Lenses (IOL)

The purpose of this study is to clinically evaluate the visual performance of two commercially available presbyopia-correcting Trifocal IOLs.

Subjects will attend a total of 9 visits (6 postoperative) over a 7 month period.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of bilateral cataracts with planned clear cornea cataract removal;
* Able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures;
* Calculated lens power between 13.0 and 30.0 Diopters (D);
* Preoperative Best-corrected distance visual acuity (BCDVA) worse than 0.20 logMAR (ie, 0.22 logMAR or worse) in at least one eye;
* Potential postoperative BCDVA of 0.20 logMAR or better in both eyes. Note: Subjects with any pathology that could reduce visual potential should not be enrolled in this trial;
* Preoperative regular corneal astigmatism of \< 1.00 D, in both eyes;
* Clear intraocular media other than cataract in both eyes;
* Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

* Reasonably expected to require an ocular surgical treatment at any time during the study (other than YAG capsulotomy);
* Previous refractive surgery or planned refractive surgery procedures throughout the entire duration of participation in the clinical study (including, but not limited to LASIK, astigmatic keratotomy and limbal relaxing incisions);
* Clinically significant corneal abnormalities including corneal dystrophy, inflammation or edema;
* Amblyopia;
* Previous corneal transplant;
* Any recurrent severe anterior or posterior segment inflammation of any etiology, and/or history of any disease producing an intraocular inflammatory reaction;
* Rubella, congenital, traumatic, or complicated cataracts;
* Glaucoma (uncontrolled or controlled with medication);
* Degenerative eye disorders;
* History of or current retinal conditions or predisposition to retinal conditions, previous history of, or a predisposition to, retinal detachment or presence of diabetic retinopathy;
* Optic nerve atrophy;
* Expected to require retinal laser treatment;
* Color vision deficiencies;
* Pregnant or lactating (current or planned during the course of the study);
* Other protocol-specified exclusion criteria may apply.
Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

The purpose of this observational study is to evaluate the effectiveness and safety of generic imatinib under usual clinical practice in patients of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) patients in chronic phase (CP) in Egypt

An observational, multi-center, prospective cohort study to assess the effectiveness and safety of generic Imatinib (Carcemia®) in patients with Ph+ CML who are newly diagnosed or patients who will be switched from the reference product (Glivec® ) to Carcemia® where treatment will be prescribed by the investigator in accordance with clinical practice where no visits or intervention(s) additional to the daily practice will be performed.

Eligible Ph+ CML patients in both cohorts will be followed up for a total of 18 months.

Eligibility Criteria:
Inclusion Criteria:

First cohort (newly diagnosed patients):

* Age ≥18 years
* Newly diagnosed patients with Ph+ CML in CP, with or without the presence of other cytogenetic abnormalities at the time of diagnosis
* Treatment naïve patients with confirmed diagnosis within 3 months of study enrolment
* Levels of liver aminotransferases and serum bilirubin ≤ 2 times the upper limit of the normal range, and serum creatinine ≤1.5 times the upper limit of the normal range
* Written informed consent

Second cohort (switched patients):

* Age ≥18 years
* Ph+ CML patients in CP currently treated with Glivec®, with or without the presence of other cytogenetic abnormalities at the time of switch
* Levels of liver aminotransferases and serum bilirubin ≤ 2 times the upper limit of the normal range and serum creatinine ≤1.5 times the upper limit of the normal range
* Written informed consent

Exclusion Criteria:

* CML in accelerated phase (AP) at enrollment except patients in AP with the presence of other cytogenetic abnormalities at the time of diagnosis
* CML in BP at enrollment
* Patients who meet any of the contraindications to the administration of the study drug according to the approved Summary of Product Characteristics
In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy

This study aims to assess the degree of artemisinin resistance in adult and pediatric subjects presenting with uncomplicated falciparum malaria in Western Kenya. The study treatments will be Artemether Lumefantrine (AL) and Artesunate Mefloquine (ASMQ).

Data generated by this study will provide a snapshot of the current situation regarding P. falciparum sensitivity to ACTs in Western Kenya. By having subjects in one of the study arms receive artesunate and then the partner drug after completion of the artemisinin phase will enable the accurate evaluation of the artemisinin derivative without the confounding influence of the partner drug. Sequential administration of the components of an ACT drug is recognized by the WHO as one of the ways in which ACTs can be administered. There will be close follow-up of the subjects throughout the duration of the study, and as such, subjects who fail to respond adequately will receive prompt rescue treatment. Since it is largely expected that most subjects in Western Kenya will have satisfactory responses to ACTs, data from this study will provide baseline information regarding parasite characteristics when compared to data from Thailand, an area that has reported resistance to ACTs. This, in turn, will potentially enable the identification of key markers, both in the host and the parasite, that may assist in the early detection of resistance, and also to better understand the development of resistance to ACTs. As such, the data generated from this study, both on its own and when compared to and pooled with data from similar studies that will be conducted in Peru and Thailand, will potentially inform both local and international policy regarding ACT use for the treatment of uncomplicated P. falciparum malaria.

Eligibility Criteria:
Inclusion Criteria:

* Adult/child aged between 6 months and 65 years inclusive (minimum weight 11kg), presenting with a measured temperature of ≥37.5 C, or history of fever within 24 hours prior to presentation
* Mono-infection with Plasmodium falciparum
* Baseline parasitemia of 2000 - 200,000 asexual parasites/µl
* Ability to provide informed consent
* Willingness and ability to comply with the study protocol for the duration of the study
* Willingness to remain in the hospital for 3 days

Exclusion Criteria:

* Presence of signs of severe malaria as defined by WHO
* Presence of severe anemia, defined as hemoglobin level below 6 g/dl
* Presence of mixed Plasmodium infection, or mono-infection of non-falciparum Plasmodium
* Inability to take oral medication
* History of allergy or contraindications to the study treatments
* Lactating or pregnant females
* Any condition that the investigator feels will result in an unfavorable outcome should the potential subject participate in the study
The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2

To evaluate a pharmacokinetic drug interaction between AJU-A51R1 and AJU-A51R2 in healthy male volunteers.

This study is to investigate drug-drug interaction between AJU-A51R1 and AJU-A51R2.

Eligibility Criteria:
Inclusion Criteria:

1. Individuals whose age is over 19 and under 65 years old when visiting for initial screening test.
2. Body mass index(BMI) between 17.5\~30.5 kg/m\^2 and the body weight must be over 55 kg(men) or 45 kg(women) (Body mass index (BMI) = weight (kg) / height (m)\^2) .
3. Individuals with no congenital or chronic disease in three years, no history of symptoms in internal treatment, or no knowledge in the area.
4. Due to the special characteristics of drugs, the participators must be qualified to do the clinical screening after examined through hematology test and blood chemistry analysis, urinary test, the electrocardiogram (ECG), and etc.
5. The participants must be volunteered and sign in an informed consent document proven by Chonbuk National University IRB before joining a study to show that he was given informed the purpose of tests and the special characteristics of drugs.
6. Individuals who agreed proper contraception during the study
7. The participants must have an ability and willingness to participate throughout the entire trials.

Exclusion Criteria:

1. Individuals with a medical evidence or a history (excluding dental history of periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune disease.
2. Individual who had a history of gastrointestinal related disease which can be affected the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's disease) or surgeries (except a simple appendectomy or herniotomy).
3. Individual who had following results after examination(a. ALT or AST \> twice higher than Upper limit of normal value).
4. Individual Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (12%) (125 mL) = 12g).
5. Individual whose blood pressure \< 90 or ≥160(systolic blood pressure) or \< 50 or ≥ 100(diastolic blood pressure).
6. Individuals who had been administered investigational product(s) from other clinical study or bioequivalence study within 180 days prior to the first dose of this study(except when subject have not taken investigational product(s)).
7. Individual who had a medical history of alcohol and drug abuses.
8. Individual who had taken a drug that has a control of metabolic rate (activation or inhibition) in 30 days before the first taking of clinical testing drug.
9. Individual who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders.
10. A person who is not determined unsuitable to participate in this test by the researchers.
Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma

The purpose of this study is to investigate the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency.

the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency

follow asthma severity score and length of stay

Eligibility Criteria:
Inclusion Criteria:

* Pediatric asthma patients with moderate to severe exacerbation

Exclusion Criteria:

* Known allergy to magnesium sulfate
* History of neuromuscular disease, cardiac disease, renal disease, or underlying chronic lung disease
* Use of oral steroid medication within 72 hours of presentation
* Radiographic evidence of pneumonia at presentation
* Administration of intravenous magnesium sulfate prior to study enrollment
Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions

This clinical trial aims to learn if a multimodal artificial intelligence (AI) model can enhance the diagnosis of pancreatic solid lesions. The main questions it aims to answer are:

1. Does the AI model enhance the diagnostic performance of endoscopists in diagnosing pancreatic solid lesions?
2. Does the addition of interpretability analysis further improve the diagnostic performance of the assisted endoscopists? Researchers will compare the diagnostic performance of endoscopists with or without the assistance of the AI model.

Participants will:

1. Their clinical data will be prospectively collected.
2. They will be randomized to the AI-assist group and the conventional diagnosis group.

The investigators have previously developed a multimodal AI model (Joint-AI) based on endoscopic ultrasound images and clinical data to diagnose pancreatic solid lesions. This study aims to improve the Joint-AI model's performance with a prospectively collected dataset and validate it through a randomized controlled clinical trial.

Eligibility Criteria:
Inclusion Criteria:

* Imaging examinations (MRI, CT, B-ultrasound) show a solid mass in the pancreas, which requires endoscopic ultrasound guided-fine needle aspiration/biopsy (EUS-FNA/B) to clarify the nature of the lesion in patients.
* Written consent provided

Exclusion Criteria:

* Age under 18 years old
Immune Effects of Low-dose Naltrexone in ME/CFS

The main objective of this study is to test if naltrexone, when taken in low doses, has an anti-inflammatory effect that may be associated with positive clinical outcomes in people with chronic fatigue syndrome (CFS). In part, the present study, is a continuation of prior work in which we showed that chronic fatigue symptoms are associated with immune activity, and that low-dose naltrexone might exert anti-inflammatory effects in fibromyalgia, which is thought to share some pathophysiological and clinical characteristics with CFS.


Eligibility Criteria:
Inclusion Criteria:

1. Meet the 1994 Case Definition criteria for CFS (assessed through semi-structured interview and the DePaul University Fatigue Questionnaire):

* Criteria:

  * Severe chronic fatigue ≥6 consecutive months not due to ongoing exertion or other medical condition associated with fatigue;
  * Fatigue interferes with daily activities and work;
  * Reports ≥4 symptoms that started with or after the fatigue, from:
* Post-exertion malaise \>24 hours
* Unrefreshing sleep
* Short-term memory or concentration impairment
* Muscle pain
* Joint pain without swelling or redness
* Headaches of a new type/pattern/severity
* Lymph node tenderness
* Frequent or recurring sore throat 3. CFS symptoms for ≥12 months 4. Participant completes daily self-report during the 4-week baseline period; 5. Able to attend UAB on all scheduled appointments

Exclusion Criteria:

1. Blood draw contraindicated or otherwise not able to be performed
2. High-sensitivity c-reactive protein (HS-CRP) ≥3 mg/L
3. Erythrocyte sedimentation rate (ESR) \>60 mm/hr
4. Positive rheumatoid factor
5. Positive anti-nuclear antibody (ANA)
6. Levels of thyroid stimulating hormone or free thyroxine outside UAB lab reference values
7. Diagnosed rheumatological or auto-immune condition
8. Clotting disorder
9. Use of blood thinning medication
10. Oral temperature \>100˚F at baseline
11. Febrile illness or use of antibiotics in the 4 weeks before study commencement;
12. Planned surgery or procedures during the study period, or operated on in the 4 weeks before study commencement
13. Pregnant or planning on becoming pregnant within 6 months
14. Regular use of any anti-inflammatory medication (such as aspirin, ibuprofen, naproxen)
15. Known allergy or adverse effects following naltrexone or naloxone administration
16. Opioid use (self-reported or positive on urine test)
17. Significant psychological comorbidity that in the discretion of the investigator compromises study integrity and/or a baseline HADS depression subscale score of ≥16
18. Current litigation or worker's compensation claim
19. Current participation in another treatment trial
20. Vaccinated in the 4 weeks before study commencement (vaccination during the study period is allowed as long as the drug is administered at least 4 weeks prior to a study blood draw).